Literature DB >> 22386823

Overview of microbicides for the prevention of human immunodeficiency virus.

Salim S Abdool Karim1, Cheryl Baxter.   

Abstract

Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four classes of candidate microbicides have been tested to date: those that (1) enhance the natural defences in the vagina to inactivate HIV; (2) inactivate HIV in the vagina; (3) prevent HIV from attaching to, and fusing with, the host cells; and (4) prevent HIV from replicating in genital tract host cells. Despite numerous disappointing efficacy trial results over the past 20 years, substantial progress is now being made in microbicide development after the release of the CAPRISA 004 trial, which provided proof-of-concept that topical antiretroviral microbicides can prevent sexual transmission of HIV and herpes simplex type-2 infection. Microbicides, which fill an important gap for women-controlled prevention methods, have the potential to alter the course of the HIV pandemic.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386823      PMCID: PMC3383397          DOI: 10.1016/j.bpobgyn.2012.01.010

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  50 in total

1.  Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya.

Authors:  M Schwandt; C Morris; A Ferguson; E Ngugi; S Moses
Journal:  Sex Transm Infect       Date:  2006-06-21       Impact factor: 3.519

2.  Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa.

Authors:  S C Kalichman; L C Simbayi; D Cain; S Jooste
Journal:  Sex Transm Infect       Date:  2009-05-07       Impact factor: 3.519

3.  Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.

Authors:  E De Clercq
Journal:  Biochem Pharmacol       Date:  2006-09-19       Impact factor: 5.858

4.  Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.

Authors:  Lut Van Damme; Roshini Govinden; Florence M Mirembe; Fernand Guédou; Suniti Solomon; Marissa L Becker; B S Pradeep; A K Krishnan; Michel Alary; Bina Pande; Gita Ramjee; Jennifer Deese; Tania Crucitti; Doug Taylor
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

5.  Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  Stephanie Skoler-Karpoff; Gita Ramjee; Khatija Ahmed; Lydia Altini; Marlena Gehret Plagianos; Barbara Friedland; Sumen Govender; Alana De Kock; Nazira Cassim; Thesla Palanee; Gregory Dozier; Robin Maguire; Pekka Lahteenmaki
Journal:  Lancet       Date:  2008-12-06       Impact factor: 79.321

6.  In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.

Authors:  Lisa C Rohan; Bernard J Moncla; Ratiya Pamela Kunjara Na Ayudhya; Marilyn Cost; Yunda Huang; Fang Gai; Nicole Billitto; J D Lynam; Kara Pryke; Phillip Graebing; Nicole Hopkins; James F Rooney; David Friend; Charlene S Dezzutti
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

Review 7.  Men who have sex with men and HIV/AIDS in sub-Saharan Africa.

Authors:  Adrian D Smith; Placide Tapsoba; Norbert Peshu; Eduard J Sanders; Harold W Jaffe
Journal:  Lancet       Date:  2009-07-17       Impact factor: 79.321

Review 8.  Critical issues in mucosal immunity for HIV-1 vaccine development.

Authors:  Barton F Haynes; Robin J Shattock
Journal:  J Allergy Clin Immunol       Date:  2008-05-12       Impact factor: 10.793

9.  SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.

Authors:  Paul J Feldblum; Adesina Adeiga; Rashidi Bakare; Silver Wevill; Anja Lendvay; Fatimah Obadaki; M Onikepe Olayemi; Lily Wang; Kavita Nanda; Wes Rountree
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

10.  The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study.

Authors:  Debby C J Vissers; Hélène A C M Voeten; Nico J D Nagelkerke; J Dik F Habbema; Sake J de Vlas
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

View more
  12 in total

Review 1.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

2.  Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.

Authors:  José das Neves; Francisca Araújo; Fernanda Andrade; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Pharm Res       Date:  2014-01-22       Impact factor: 4.200

3.  Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.

Authors:  Gita N Shankar; Carsten Alt
Journal:  J Antimicrob Chemother       Date:  2014-08-19       Impact factor: 5.790

4.  Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues.

Authors:  Ai Tsuiki; Wei Luo; Tara Henning; Sundaram Vishwanathan; Chuong Dinh; Debra Adams; Elizabeth Sweeney; James Mitchell; Shannon Bachman; Prachi Sharma; Nathaniel Powell; Michael Hendry; Janet McNicholl; Ellen Kersh
Journal:  J Med Primatol       Date:  2013-01-12       Impact factor: 0.667

5.  Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.

Authors:  Abhijit A Date; Annemarie Shibata; Michael Goede; Bridget Sanford; Krista La Bruzzo; Michel Belshan; Christopher J Destache
Journal:  Antiviral Res       Date:  2012-10-03       Impact factor: 5.970

6.  Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.

Authors:  Milena Veselinovic; C Preston Neff; Leila R Mulder; Ramesh Akkina
Journal:  Virology       Date:  2012-07-24       Impact factor: 3.616

7.  In vivo anti-herpes simplex virus activity of a sulfated derivative of Agaricus brasiliensis mycelial polysaccharide.

Authors:  F T G S Cardozo; I V Larsen; E V Carballo; G Jose; R A Stern; R C Brummel; C M Camelini; M J Rossi; C M O Simões; C R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

8.  Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention.

Authors:  Ayman Akil; Hrushikesh Agashe; Charlene S Dezzutti; Bernard J Moncla; Sharon L Hillier; Brid Devlin; Yuan Shi; Kevin Uranker; Lisa Cencia Rohan
Journal:  Pharm Res       Date:  2014-07-31       Impact factor: 4.200

9.  Gene Expression Profiling of Human Vaginal Cells In Vitro Discriminates Compounds with Pro-Inflammatory and Mucosa-Altering Properties: Novel Biomarkers for Preclinical Testing of HIV Microbicide Candidates.

Authors:  Irina A Zalenskaya; Theresa Joseph; Jasmin Bavarva; Nazita Yousefieh; Suzanne S Jackson; Titilayo Fashemi; Hidemi S Yamamoto; Robert Settlage; Raina N Fichorova; Gustavo F Doncel
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

10.  Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV.

Authors:  Evangelia Vamvaka; Elsa Arcalis; Koreen Ramessar; Abbey Evans; Barry R O'Keefe; Robin J Shattock; Vicente Medina; Eva Stöger; Paul Christou; Teresa Capell
Journal:  Plant Biotechnol J       Date:  2016-01-23       Impact factor: 9.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.